Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)
Study seeks to understand how HIV-infected microglia and substance use disorder impact brain health, paving way for improved treatments.
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: July 14, 2025 (Letter of Intent & Open Date) | August 14, 2025 (Application Due Date) | August 15, 2025 (Expiration)
Funding Amounts: Total program: $2.5M in FY 2026; 3–6 awards; budgets not limited but must reflect project needs; up to 5 years per project.
Summary: Supports research to define how HIV-infected microglia and substance use disorder interact to drive brain region- and cell-type-specific neuropathology.
Key Information: Clinical trials are not allowed; applications relying solely on in vitro models or focused only on alcohol use are not responsive.
Description
This funding opportunity, issued by the National Institute on Drug Abuse (NIDA) at NIH, seeks applications that use advanced quantitative protein profiling to investigate the mechanistic roles of altered protein interaction networks in microglia within the context of comorbid HIV and substance use disorder (SUD). The goal is to generate brain region- and cell-type-specific microglial protein profiles and use these data to elucidate how HIV-harboring microglia contribute to neuropathologies unique to the co-occurrence of HIV and SUD.
Research should address two phases:
- R61 phase: Develop and apply quantitative analytical approaches to measure protein interaction networks in microglia, comparing the effects of HIV infection and drug exposure (alone and together).
- R33 phase: Extend these methods to in vivo models of comorbid HIV and SUD, analyzing protein interaction networks and cell signaling dynamics.
The ultimate aim is to provide foundational knowledge that could inform future therapeutic strategies for individuals with HIV and SUD.
